Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Sponsor: Betta Pharmaceuticals Co., Ltd.
Summary
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Official title: A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-01-29
Completion Date
2029-10-28
Last Updated
2026-09-18
Healthy Volunteers
No
Conditions
Interventions
BPI-572270
Oral Tablets
Locations (7)
Blacktown Hospital
Blacktown, New South Wales, Australia
Scientia Clinical Research
Randwick, New South Wales, Australia
GenesisCare St Leonards, 7 Westbourne St, St Leonards
Sydney, New South Wales, Australia
Southern Oncology Clinical Research Unit (SOCRU)
Bedford Park, South Australia, Australia
Warringal Private Hospital
Heidelberg, Victoria, Australia
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China